QSAM Stock Overview
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
QSAM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.14 |
| 52 Week High | US$8.14 |
| 52 Week Low | US$4.00 |
| Beta | 1.81 |
| 1 Month Change | 7.11% |
| 3 Month Change | 53.58% |
| 1 Year Change | 33.44% |
| 3 Year Change | -47.82% |
| 5 Year Change | -45.73% |
| Change since IPO | -98.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| QSAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 1.5% | 1.2% |
| 1Y | 33.4% | 1.1% | 24.7% |
Return vs Industry: QSAM exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: QSAM exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| QSAM volatility | |
|---|---|
| QSAM Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QSAM's share price has been volatile over the past 3 months.
Volatility Over Time: QSAM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | Doug Baum | www.qsambio.com |
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020.
QSAM Biosciences, Inc. Fundamentals Summary
| QSAM fundamental statistics | |
|---|---|
| Market cap | US$36.19m |
| Earnings (TTM) | -US$5.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.0x
P/E RatioIs QSAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QSAM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.16m |
| Earnings | -US$5.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.1% |
How did QSAM perform over the long term?
See historical performance and comparison